Enanta Pharmaceuticals | ENTA - Ativo Circulante





Ativo Circulante Alterar Data
AbbVie USD 33.53B 4.47B 2026-03
Amgen USD 31.48B 2.42B 2026-03
Anika Therapeutics USD 93.56M 9.8M 2026-03
Arrowhead Research USD 1.84B 665.36M 2026-03
AstraZeneca USD 29.61B 890M 2026-03
BioCryst Pharmaceuticals USD 373.62M 30.72M 2026-03
Biogen USD 9.19B 216.3M 2026-03
Bristol-Myers Squibb USD 27.21B 2.18B 2026-03
Enanta Pharmaceuticals USD 198.68M 5.65M 2025-12
Gilead Sciences USD 18.64B 1.25B 2026-03
GlaxoSmithKline GBP 17.76B 251M 2026-03
Halozyme Therapeutics USD 1B 177.83M 2026-03
Heron Therapeutics USD 228.98M 9.08M 2026-03
Immunic USD 188.76M 165.89M 2026-03
Incyte USD 5.48B 460.36M 2026-03
Insmed USD 1.61B 181.04M 2026-03
Ionis Pharmaceuticals USD 2.94B 52M 2026-03
J&J USD 59.17B 3.55B 2026-03
Karyopharm Therapeutics USD 103.15M 13.4M 2025-12
Ligand Pharmaceuticals USD 865.42M 33.14M 2026-03
Merck USD 35.02B 8.5B 2026-03
Neurocrine Biosciences USD 2.44B 86.6M 2026-03
Novartis USD 26.61B 3.85B 2026-03
Novavax USD 850.82M 127.46M 2026-03
Pfizer USD 42.82B 76M 2026-03
PTC Therapeutics USD 2.25B 19.94M 2026-03
Roche Holding CHF 38.73B 3.03B 2025-12
Sarepta Therapeutics USD 2.31B 228.06M 2026-03
Vertex Pharmaceuticals USD 11.73B 529.3M 2026-03